Completed PHASE2 INTERVENTIONAL 1-arm NCT00170573

Caelyx Biweekly in Heavily Pretreated Patients With Relapsed Ovarian Cancer

Comparison of Quality of Life in Patients With Platinum-sensitive Recurrent Ovarian, Fallopian Tube and Peritoneal Cancer When Treated With Treatment With Trabectedin/PLD or Standard Platinum-based Therapy

Sponsor: North Eastern German Society of Gynaecological Oncology

Conditions Ovarian Cancer

Interventions Caelyx

Updated 7 times since 2017 Last updated: Nov 27, 2024 Started: Sep 30, 2001 Primary completion: Apr 30, 2009 Completion: Aug 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00170573, this PHASE2 trial focuses on Ovarian Cancer and remains completed. Sponsored by North Eastern German Society of Gynaecological Oncology, it has been updated 7 times since 2001, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Jan 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Jan 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jan 2020 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Jun 2018 — Jan 2020 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Sep 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

North Eastern German Society of Gynaecological Oncology

Data source: North Eastern German Society of Gynaecological Oncology

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.